SIRAKI 02 Posthoc Analysis.

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 343 participants.

Also called NCT06781294

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 343 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06781294
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Spain (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06781294. Randomized; quadruple masking; primary purpose treatment. Start 2024-10-01 (actual); primary completion 2026-11-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
SIRAKI 02 Posthoc Analysis.
Acronym
OXI-SAFE-CEC
Condition
Cardiac Surgery Requiring Cardiopulmonary Bypass
Condition
Kidney Failure, Acute
Intervention (Device)
Extracorporeal Cytokine hemadsorption therapy
Lead sponsor
Hospital Universitari de Bellvitge (class: other)
Collaborator
University of Barcelona (class: other)
Collaborator
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (class: other)
Collaborator
Germans Trias i Pujol Hospital (class: other)
Collaborator
Institut d'Investigació Biomèdica de Bellvitge (class: other)

Record details

Record id
cardio:ct-nct06781294
Content hash
e7c68ba05cf55865b9d868880943218cb75948e0d18321be2ad0647ca8d115e9